Liquid formulation containing doxorubicin-loaded lipid-core nanocapsules: Cytotoxicity in human breast cancer cell line and in vitro uptake mechanism.
Mater Sci Eng C Mater Biol Appl
; 76: 374-382, 2017 Jul 01.
Article
em En
| MEDLINE
| ID: mdl-28482541
Cancer is a major public health problem in the world, being breast cancer the most frequent cancer affecting women. Despite advances in detection and treatment, mortality rates remain high. Therefore, new approaches for breast cancer treatments are necessary. In this study, our objective was to develop a liquid formulation containing doxorubicin-loaded lipid-core nanocapsules (DOX-LNC), to evaluate the in vitro antiproliferative activity and to determine the nanocapsules uptake by MCF-7 cells. Lipid-core nanocapsules (LNC), blank formulation, and DOX-LNC, proposed treatment, were prepared by self-assembling using the solvent displacement method. Hydrodynamic mean diameters (z-average) were respectively 191±31nm and 230±23nm presenting narrow size distributions. Drug content was 0.102±0.029mgmL-1 with an encapsulation efficiency higher than 90%. Formulations were applied to semiconfluent MCF-7 cells. After 24h, LNC showed no cytotoxicity, while DOX-LNC showed an IC50 of 4.49 micromolar. After 72h of incubation, DOX-LNC showed an IC50 of 1.60 micromolar demonstrating a sustained effect. The nanocapsules were internalized by endocytosis mediated by caveolin and by fluid phase endocytosis, which are active transport mechanisms. In conclusion, the liquid formulation containing DOX-LNC showed to be a promising product for the breast cancer treatment opening new avenues for further in vivo studies.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
Limite:
Humans
Idioma:
En
Revista:
Mater Sci Eng C Mater Biol Appl
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Holanda